Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863510 | 1.00 | HCAR2 (0.54) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL195983 | 1.00 | HCAR2 (0.54) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL23666175 | 0.87 | HCAR2 (0.54) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL17285584 | 0.85 | HCAR2 (0.52) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL29740078 | 0.83 | HCAR2 (0.43) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL2969893 | 0.83 | HCAR2 (0.50) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL22231629 | 0.83 | HCAR2 (0.57) | HCAR2MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL22231627 | 0.83 | HCAR2 (0.57) | HCAR2MAPTNPSR1ALDH1A1ATM | |
| SCHEMBL2969895 | 0.83 | HCAR2 (0.50) | HCAR2MAPTNPSR1CA12CA1 | |
| SCHEMBL25729806 | 0.83 | HCAR2 (0.50) | HCAR2MAPTNPSR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111138596-B | Polymer electrolyte and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2022-09-30 | — | — | CN | claimed |
| CN-112824437-A | Preparation method of modified polyaramide and modified polyaramide | 欧美新材料(浙江)有限公司 | 2021-05-21 | — | — | CN | claimed |
| US-10414744-B2 | 4-sulfur pentafluoride phenol compound and preparation method therefor, and preparation method for sulfur pentafluoride substituted benzopyran compound | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences (CN) | 2019-09-17 | — | — | US | claimed |
| US-20190084957-A1 | 4-SULFUR PENTAFLUORIDE PHENOL COMPOUND AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR SULFUR PENTAFLUORIDE SUBSTITUTED BENZOPYRAN COMPOUND | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences (CN) | 2019-03-21 | — | — | US | claimed |
| EP-3428154-A1 | 4-SULFUR PENTAFLUORIDE PHENOL COMPOUND AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR SULFUR PENTAFLUORIDE SUBSTITUTED BENZOPYRAN COMPOUND | Guangzhou Institutes Of Biomedicine And Health Chinese Academy Of Sciences (CN) | 2019-01-16 | — | — | EP | claimed |
| EP-1044991-B1 | Process of preparing curable compositions and compositions therefrom | ROHM & HAAS (US) | 2004-02-11 | — | — | EP | claimed |
| US-20020137857-A1 | Forming an oligomer containing reactive functional groups,and reacting a modifier that also contains reactive function groups with the oligomer | ROHM AND HAAS COMPANY | 2002-09-26 | — | — | US | claimed |
| EP-1044991-A1 | Process of preparing curable compositions and compositions therefrom | ROHM AND HAAS COMPANY (US) | 2000-10-18 | — | — | EP | claimed |
| US-12544356-B2 | Combination of a chromene compound and a second active agent | Euclises Pharmaceuticals, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240392220-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. | 2024-11-28 | — | — | US | disclosed |
| EP-4408967-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024070091-A1 | ONIUM SALT, PHOTOACID GENERATOR, POLYMER, RESIST COMPOSITION, AND METHOD FOR MANUFACTURING DEVICE USING SAID RESIST COMPOSITION | 東洋合成工業株式会社 | 2024-04-04 | — | — | WO | disclosed |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2023192814-A1 | BENZAMIDE ENAMINONE DERIVATIVES AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, EASTERN SHORE (US) | 2023-10-05 | — | — | WO | disclosed |
| US-4404203-A | AND 6-PHENYL-4,5-DIHYDRO-3/2H/-PYRIDAZINONES | WARNER-LAMBERT COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
| US-4325877-A | Production of intermediates for enzyme inhibitors | RICHARDSON-MERRELL INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4277395-A | OF ELASTASE; OLIGOPEPTIDES | RICHARDSON-MERRELL INC. (US) | 1981-07-07 | — | — | US | disclosed |
| EP-0021883-A2 | N-acyl-amino acid derivatives and pharmaceutical compositions containing them, intermediates and starting compounds | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-01-07 | — | — | EP | disclosed |
| US-4241076-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1980-12-23 | — | — | US | disclosed |
| US-4154935-A | Halogen substituted mercaptoacylamino acids | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | ENTPD5, ENTPD1, NT5E | HCAR2 1455/4885MAPT 1380/4885NPSR1 728/4885 |
| US-12544356-B2 | Combination of a chromene compound and a second active agent | CD274, ICOS, PDCD1 | HCAR2 1333/4885MAPT 2317/4885NPSR1 938/4885 |
| US-20190084957-A1 | 4-SULFUR PENTAFLUORIDE PHENOL COMPOUND AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR SULFUR PENTAFLUORIDE SUBSTITUTED BENZOPYRAN COMPOUND | SALL4, FGFR4, CYP4F11 | HCAR2 2740/4885MAPT 3811/4885NPSR1 1583/4885 |
| US-10414744-B2 | 4-sulfur pentafluoride phenol compound and preparation method therefor, and preparation method for sulfur pentafluoride substituted benzopyran compound | SALL4, FGFR4, CYP4F11 | HCAR2 2740/4885MAPT 3811/4885NPSR1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.